Compared to intravenous (IV) delivery, RYBREVANT FASPROâ"¢ significantly reduced administration time from several hours to approximately five minutes and demonstrated an approximately fivefold reduction in administration-related reactions (ARRs) (13 percent in SC vs 66 percent in IV arm). "Formulated with our leading ENHANZE drug delivery technology, RYBREVANT FASPROâ"¢ has the potential to make administration faster and more convenient for patients and their families compared to intravenous administration, ...

RYBREVANT FASPRO1-5â"¢, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related reactions 6Approval builds on previously reported Phase 3 MARIPOSA data showing unmatched overall survival benefit of this chemotherapy-free regimen, projected to exceed four years 1 HORSHAM, Pa., Dec. 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administra ...